| SGLT-2抑制剂和GLP-1受体激动剂的心血管安全性研究进展 |
| |
| 引用本文： | 赖彦岚,黄爱文,张丽丽,廖小兰,赵丽君,宋洪涛. SGLT-2抑制剂和GLP-1受体激动剂的心血管安全性研究进展[J]. 药学实践杂志, 2020, 38(6): 496-500,567 |
| |
| 作者姓名： | 赖彦岚 黄爱文 张丽丽 廖小兰 赵丽君 宋洪涛 |
| |
| 作者单位： | 中国人民解放军联勤保障部队第九〇〇医院药学科，福建 福州 350025;沈阳药科大学生命科学与生物制药学院，辽宁 沈阳 110016 |
| |
| 摘 要： | 2型糖尿病是动脉粥样硬化性心血管疾病发病的高危因素。研究发现，钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂、胰高血糖素样多肽-1(GLP-1)受体激动剂对2型糖尿病合并心血管疾病的患者具有心血管保护作用。故从心血管安全性试验及其Meta分析、网状Meta分析方面，对SGLT-2抑制剂、GLP-1受体激动剂的心血管安全性研究进展进行归纳和总结。
|
| 关 键 词： | SGLT-2抑制剂 GLP-1受体激动剂 2型糖尿病 心血管安全性 |
| 收稿时间： | 2020-06-16 |
| 修稿时间： | 2020-09-07 |
Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists |
| |
| LAI Yanlan,HUANG Aiwen,ZHANG Lili,LIAO Xiaolan,ZHAO Lijun,SONG Hongtao. Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists[J]. The Journal of Pharmaceutical Practice, 2020, 38(6): 496-500,567 |
| |
| Authors: | LAI Yanlan HUANG Aiwen ZHANG Lili LIAO Xiaolan ZHAO Lijun SONG Hongtao |
| |
| Affiliation: | Department of Pharmacy, No. 900 Hospital of Joint Logistics Support Force of the PLA, Fuzhou 350025, China;Department of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China |
| |
| Abstract: | Type 2 diabetes is a high risk factor for atherosclerotic cardiovascular disease. Studies have found that SGLT-2 inhibitor and GLP-1 receptor agonists have cardiovascular protective effects in patients with type 2 diabetes and cardiovascular disease. Therefore, from the aspects of cardiovascular safety test and its Meta-analysis and net-like Meta-analysis, the research progress of cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists is summarized. |
| |
| Keywords: | SGLT-2 inhibitors GLP-1 receptor agonists type 2 diabetes cardiovascular safety |
|
| 点击此处可从《药学实践杂志》浏览原始摘要信息 |
|
点击此处可从《药学实践杂志》下载全文 |
